Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Authorizes Yale’s SalivaDirect '$10' Rapid COVID-19 Test

Executive Summary

The agency says the test is “groundbreaking.” The Yale School of Public Health is giving away the test methodology, which can be run with equipment labs already have.

You may also be interested in...



FDA Authorizes Abbott’s '$5, 15 Minute' COVID-19 Antigen Test

The BinaxNOW COVID-19 Ag Card portable lateral flow test, which delivers rapid results with no instrumentation, could be a “game changer” in the effort to reopen schools and other crowded places.

FDA Boosts Development Of OTC COVID-19 Tests With New Template

A new template from the US FDA explains what information the agency wants to see in regulating COVID-19 tests to be performed outside the laboratory environment.

News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More

Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT142587

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel